PT  - JOURNAL ARTICLE
AU  - Greiffo, Flavia R.
AU  - Eickelberg, Oliver
AU  - Fernandez, Isis E.
TI  - Systems medicine advances in interstitial lung disease
AID  - 10.1183/16000617.0021-2017
DP  - 2017 Sep 30
TA  - European Respiratory Review
PG  - 170021
VI  - 26
IP  - 145
4099  - http://err.ersjournals.com/content/26/145/170021.short
4100  - http://err.ersjournals.com/content/26/145/170021.full
SO  - EUROPEAN RESPIRATORY REVIEW2017 Sep 30; 26
AB  - Fibrotic lung diseases involve subject–environment interactions, together with dysregulated homeostatic processes, impaired DNA repair and distorted immune functions. Systems medicine-based approaches are used to analyse diseases in a holistic manner, by integrating systems biology platforms along with clinical parameters, for the purpose of understanding disease origin, progression, exacerbation and remission.Interstitial lung diseases (ILDs) refer to a heterogeneous group of complex fibrotic diseases. The increase of systems medicine-based approaches in the understanding of ILDs provides exceptional advantages by improving diagnostics, unravelling phenotypical differences, and stratifying patient populations by predictable outcomes and personalised treatments. This review discusses the state-of-the-art contributions of systems medicine-based approaches in ILDs over the past 5 years.Systems medicine provides critical advances in understanding and molecular fingerprinting interstitial lung diseases http://ow.ly/phXg30dWVvv